SPRO vs. RIGL
SPRO (Spero Therapeutics, Inc.) and RIGL (Rigel Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, SPRO returned -38.54%/yr vs -1.65%/yr for RIGL. Their 0.26 correlation means their historical movements had little consistent relationship.
Performance
SPRO vs. RIGL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SPRO achieves a -49.79% return, which is significantly lower than RIGL's -14.06% return.
SPRO
- 1D
- -2.50%
- 1M
- -46.82%
- 6M
- -46.58%
- YTD
- -49.79%
- 1Y
- -49.13%
- 3Y*
- -8.35%
- 5Y*
- -38.54%
- 10Y*
- —
- ALL TIME*
- -24.24%
RIGL
- 1D
- -3.28%
- 1M
- -4.93%
- 6M
- 5.59%
- YTD
- -14.06%
- 1Y
- 68.01%
- 3Y*
- 40.40%
- 5Y*
- -1.65%
- 10Y*
- 3.86%
- ALL TIME*
- -10.60%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $11.43M | $14.01M | $13.32M | |
| $3.27M | $3.26M | $3.15M |
SPRO vs. RIGL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SPRO Spero Therapeutics, Inc. | -49.79% | 126.21% | -29.93% | -15.03% | -89.19% | -17.43% | 101.66% | 56.34% | -47.66% | -11.32% |
RIGL Rigel Pharmaceuticals, Inc. | -14.06% | 154.64% | 16.00% | -3.33% | -43.40% | -24.29% | 63.55% | -6.96% | -40.72% | 4.02% |
Correlation
The correlation between SPRO and RIGL is 0.20, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.20 |
Correlation (3Y) Balances recent behavior with more history. | 0.19 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.23 |
Correlation (All Time) Calculated using the full available price history since Nov 2, 2017 | 0.26 |
Fundamentals
SPRO:
$67.74M
RIGL:
$681.06M
SPRO:
$0.39
RIGL:
$18.94
SPRO:
3.01
RIGL:
1.94
SPRO:
1.23
RIGL:
2.36
SPRO:
1.27
RIGL:
1.81
SPRO:
$54.77M
RIGL:
$299.77M
SPRO:
$54.51M
RIGL:
$279.95M
SPRO:
$12.49M
RIGL:
$125.80M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SPRO vs. RIGL — Risk / Return Rank
SPRO
RIGL
SPRO vs. RIGL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Spero Therapeutics, Inc. (SPRO) and Rigel Pharmaceuticals, Inc. (RIGL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SPRO | RIGL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.84 | ||
| Sortino ratioReturn per unit of downside risk | -2.87 | ||
| Omega ratioGain probability vs. loss probability | 0.87 | 1.25 | -0.37 |
| Calmar ratioReturn relative to maximum drawdown | -0.81 | 1.50 | -2.32 |
| Martin ratioReturn relative to average drawdown | -2.72 | 2.51 | -5.23 |
Loading charts...
Drawdowns
SPRO vs. RIGL - Drawdown Comparison
The maximum SPRO drawdown since its inception was -97.46%, roughly equal to the maximum RIGL drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for SPRO and RIGL.
Loading charts...
Drawdown Indicators
| SPRO | RIGL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.46% | -99.37% | +1.91% |
Max Drawdown (1Y)Largest decline over 1 year | -61.07% | -50.08% | -10.99% |
Max Drawdown (3Y)Largest decline over 3 years | -68.89% | -50.76% | -18.13% |
Max Drawdown (5Y)Largest decline over 5 years | -97.13% | -83.85% | -13.28% |
Max Drawdown (10Y)Largest decline over 10 years | — | -86.40% | — |
Current DrawdownCurrent decline from peak | -94.70% | -96.55% | +1.85% |
Average DrawdownAverage peak-to-trough decline | -62.80% | -90.93% | +28.13% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.27% | 29.86% | -11.59% |
Volatility
SPRO vs. RIGL - Volatility Comparison
Spero Therapeutics, Inc. (SPRO) has a higher volatility of 28.65% compared to Rigel Pharmaceuticals, Inc. (RIGL) at 11.97%. This indicates that SPRO's price experiences larger fluctuations and is considered to be riskier than RIGL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SPRO | RIGL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 28.65% | 11.97% | +16.68% |
Volatility (6M)Calculated over the trailing 6-month period | 54.70% | 34.77% | +19.93% |
Volatility (1Y)Calculated over the trailing 1-year period | 64.87% | 70.02% | -5.15% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 152.38% | 85.52% | +66.86% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 124.57% | 82.76% | +41.81% |
Dividends
SPRO vs. RIGL - Dividend Comparison
Neither SPRO nor RIGL has paid dividends to shareholders.
Financials
SPRO vs. RIGL - Financials Comparison
This section allows you to compare key financial metrics between Spero Therapeutics, Inc. and Rigel Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
SPRO and RIGL have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SPRO has higher volatility (28.65%) compared to RIGL (11.97%). In terms of maximum drawdown, SPRO dropped -97.46% vs RIGL's -99.37%.
RIGL currently has the higher Sharpe Ratio (1.07 vs -0.77), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SPRO and RIGL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer